Brian G. Feagan - Concepedia

Author

Brian G. Feagan

Also Known As

B FEAGAN, B Feagan, B G Feagan, B. FEAGAN, B. Feagan, B. G. FEAGAN, B. G. Feagan, B.G. Feagan, B. G. Feagan, Brian Feagan

1.3K

Publications

89.1K

Citations

136

H-Index

112

Concepts

All Affiliations

Western University University of California San Diego Robarts Clinical Trials Icahn School of Medicine at Mount Sinai University of Calgary

About

Brian G. Feagan is an author at Western University specializing in medicine, gastroenterology, and inflammation.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	55	126	22.7K
2	Public Health	7	7	556
3	Allergy	6	6	940
4	Health Sciences	4	4	236
5	Management	1	1	16

Brian G. Feagan

354

Publications

69.4K

Citations

114

H-Index

Page 1

	Year	Citations
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Stephen B. Hanauer, Brian G. Feagan, Gary R. Lichtenstein, The Lancet InflammationChronic Inflammatory DiseasesAnti-inflammatoryMaintenance InfliximabGastroenterology	2002	4.1K
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis Paul Rutgeerts, William J. Sandborn, Brian G. Feagan, New England Journal of Medicine	2005	3.8K
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis Brian G. Feagan, Paul Rutgeerts, Bruce E. Sands, New England Journal of Medicine	2013	2.8K
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease William J. Sandborn, Brian G. Feagan, Paul Rutgeerts, New England Journal of Medicine	2013	2.6K
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease Bruce E. Sands, Frank Anderson, Çharles N. Bernstein, New England Journal of Medicine	2004	2.2K
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease Brian G. Feagan, William J. Sandborn, Christopher Gasink, New England Journal of Medicine	2016	1.7K
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis William J. Sandborn, Chinyu Su, Bruce E. Sands, New England Journal of Medicine	2017	1.7K
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial Wolfgang Hueber, Bruce E. Sands, Steve Lewitzky, Gut	2012	1.5K
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial Geert D’Haens, Filip Baert, Gert Van Assche, The Lancet Autoimmune DiseaseImmunosuppressive TherapyImmunologyGastroenterologyClinical Gastroenterology	2008	1.2K
Certolizumab Pegol for the Treatment of Crohn's Disease William J. Sandborn, Brian G. Feagan, S Stoĭnov, New England Journal of Medicine	2007	1.1K

Page 1